# Clinical Benefit of 18F-FET in Glioma.

> **NCT07698457** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Primo Biotechnology Co., Ltd** · enrollment: 36 (estimated)

## Conditions studied

- Glioma
- 18F-Fluoroethyl-l-tyrosine

## Interventions

- **DIAGNOSTIC_TEST:** 18F-Fluoroethyl-l-tyrosine

## Key facts

- **NCT ID:** NCT07698457
- **Lead sponsor:** Primo Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07698457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07698457, "Clinical Benefit of 18F-FET in Glioma.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07698457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*